Letter Re: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.
作者信息
Camoz E S, Onur I D, Yildiz F
机构信息
University of Health Science, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey.
University of Health Science, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey.
出版信息
ESMO Open. 2025 May;10(5):105106. doi: 10.1016/j.esmoop.2025.105106. Epub 2025 May 9.
Abstract
摘要
相似文献
1
Letter Re: Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.信件回复：现实世界中转移性乳腺癌患者一线至二线治疗失败的相关因素。
ESMO Open. 2025 May;10(5):105106. doi: 10.1016/j.esmoop.2025.105106. Epub 2025 May 9.
2
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.现实世界中转移性乳腺癌患者一线至二线治疗失败的相关因素。
ESMO Open. 2025 Feb;10(2):104125. doi: 10.1016/j.esmoop.2024.104125. Epub 2025 Jan 21.
3
Letter response re: factors associated with first-to-second line attrition among patients with metastatic breast cancer in the real-world.关于现实世界中转移性乳腺癌患者一线至二线治疗失败相关因素的信件回复
ESMO Open. 2025 Jun;10(6):105107. doi: 10.1016/j.esmoop.2025.105107. Epub 2025 May 16.
4
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry.德国真实世界PRAEGNANT注册研究中晚期乳腺癌患者前三线治疗的损耗情况
Geburtshilfe Frauenheilkd. 2024 May 29;84(5):459-469. doi: 10.1055/a-2286-5372. eCollection 2024 May.
5
Attrition between lines of therapy and real-world outcomes of patients with HER2-positive metastatic breast cancer in Europe: a cohort study leveraging electronic medical records.欧洲HER2阳性转移性乳腺癌患者治疗线之间的损耗及真实世界结局：一项利用电子病历的队列研究
Breast Cancer Res Treat. 2025 Jan;209(2):419-430. doi: 10.1007/s10549-024-07506-4. Epub 2024 Oct 20.
6
Real-world management patterns in -mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.奥希替尼一线治疗前 - 突变型晚期非小细胞肺癌的真实世界管理模式：希腊 REFLECT 研究。
Future Oncol. 2022 Sep;18(28):3151-3164. doi: 10.2217/fon-2022-0386. Epub 2022 Aug 5.
7
Treatment Patterns and Attrition in Metastatic Renal Cell Carcinoma: Real-Life Experience from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
Clin Genitourin Cancer. 2025 Feb;23(1):102282. doi: 10.1016/j.clgc.2024.102282. Epub 2024 Nov 29.
8
Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.晚期三阴性乳腺癌一线至三线治疗的真实世界生存情况及治疗方案
Breast Cancer (Auckl). 2023 Oct 4;17:11782234231203292. doi: 10.1177/11782234231203292. eCollection 2023.
9
Rate of Viral Re-Suppression and Retention to Care Among PLHIV on Second-Line Antiretroviral Therapy at Dessie Comprehensive Specialized Hospital, Northeast Ethiopia: A Retrospective Cohort Study.埃塞俄比亚东北部德西综合专科医院接受二线抗逆转录病毒治疗的艾滋病毒感染者的病毒重新抑制率和治疗留存率：一项回顾性队列研究
HIV AIDS (Auckl). 2021 Sep 7;13:877-887. doi: 10.2147/HIV.S323445. eCollection 2021.
10
Real-world patterns of chemotherapy administration and attrition among patients with metastatic colorectal cancer.转移性结直肠癌患者化疗管理和流失的真实世界模式。
Int J Colorectal Dis. 2021 Mar;36(3):493-499. doi: 10.1007/s00384-020-03778-6. Epub 2020 Oct 17.
引用本文的文献
1
Letter response re: factors associated with first-to-second line attrition among patients with metastatic breast cancer in the real-world.关于现实世界中转移性乳腺癌患者一线至二线治疗失败相关因素的信件回复
ESMO Open. 2025 Jun;10(6):105107. doi: 10.1016/j.esmoop.2025.105107. Epub 2025 May 16.
本文引用的文献
1
Factors associated with first-to-second-line attrition among patients with metastatic breast cancer in the real world.现实世界中转移性乳腺癌患者一线至二线治疗失败的相关因素。
ESMO Open. 2025 Feb;10(2):104125. doi: 10.1016/j.esmoop.2024.104125. Epub 2025 Jan 21.
2
Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study.基于激素受体状态的 HER2 阳性乳腺癌患者的临床病理特征、治疗模式和结局：一项回顾性研究。
BMC Cancer. 2024 Sep 30;24(1):1216. doi: 10.1186/s12885-024-12974-4.
3
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer.IV 期乳腺癌不同转移部位患者的临床病理特征和生存结局。
BMC Cancer. 2019 Nov 12;19(1):1091. doi: 10.1186/s12885-019-6311-z.
4
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌的治疗
N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
Zotero 插件